熱門資訊> 正文
库拉肿瘤学未达到第三季度预期
2025-11-04 19:44
- Kura Oncology press release (KURA): Q3 GAAP EPS of -$0.85 misses by $0.43.
- Revenue of $20.75M misses by $25.58M.
- As adjusted for the two $30 million clinical trial milestone payments earned under our collaboration agreement with Kyowa Kirin, Kura had, on a pro forma basis, cash, cash equivalents and short-term investments of $609.7 million as of September 30, 2025.
More on Kura Oncology
- Kura Oncology's Ziftomenib Poised For Differentiation
- Kura Oncology, Inc. (KURA) Discusses Clinical Updates on Farnesyl Transferase Inhibitor Programs and Combination Therapies in Oncology - Slideshow
- Kura Oncology, Inc. (KURA) Discusses Clinical Updates on Farnesyl Transferase Inhibitor Programs and Combination Therapies in Oncology Transcript
- Kura Oncology Q3 2025 Earnings Preview
- Seeking Alpha’s Quant Rating on Kura Oncology
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
